Scalper1 News
Biotech InterMune (ITMN) hit a three-year high on the stock market today after UBS lifted its price target for the company on bullish expectations for a drug launch. UBS analyst Andrew Peters wrote that he expects Esbriet to become the standard of care for the lung disease idiopathic pulmonary fibrosis (IPF) once it is approved in the U.S. The drug is already sold in Europe, Canada, Japan and several other countries, but the FDA rejected Scalper1 News
Scalper1 News